-
1
-
-
84882837534
-
Signatures of mutational processes in human cancer
-
Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Borresen-Dale A.L., Boyault S., Burkhardt B., Butler A.P., Caldas C., Davies H.R., Desmedt C., Eils R., Eyfjord J.E., Foekens J.A., Greaves M., Hosoda F., Hutter B., Ilicic T., Imbeaud S., Imielinski M., Jager N., Jones D.T., Jones D., Knappskog S., Kool M., Lakhani S.R., Lopez-Otin C., Martin S., Munshi N.C., Nakamura H., Northcott P.A., Pajic M., Papaemmanuil E., Paradiso A., Pearson J.V., Puente X.S., Raine K., Ramakrishna M., Richardson A.L., Richter J., Rosenstiel P., Schlesner M., Schumacher T.N., Span P.N., Teague J.W., Totoki Y., Tutt A.N., Valdes-Mas R., van Buuren M.M., van 't Veer L., Vincent-Salomon A., Waddell N., Yates L.R., Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrain, Zucman-Rossi J., Futreal P.A., McDermott U., Lichter P., Meyerson M., Grimmond S.M., Siebert R., Campo E., Shibata T., Pfister S.M., Campbell P.J., Stratton M.R. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
-
(2013)
Nature
, vol.500
, pp. 415-421
-
-
Alexandrov, L.B.1
Nik-Zainal, S.2
Wedge, D.C.3
Aparicio, S.A.4
Behjati, S.5
Biankin, A.V.6
Bignell, G.R.7
Bolli, N.8
Borg, A.9
Borresen-Dale, A.L.10
Boyault, S.11
Burkhardt, B.12
Butler, A.P.13
Caldas, C.14
Davies, H.R.15
Desmedt, C.16
Eils, R.17
Eyfjord, J.E.18
Foekens, J.A.19
Greaves, M.20
Hosoda, F.21
Hutter, B.22
Ilicic, T.23
Imbeaud, S.24
Imielinski, M.25
Jager, N.26
Jones, D.T.27
Jones, D.28
Knappskog, S.29
Kool, M.30
Lakhani, S.R.31
Lopez-Otin, C.32
Martin, S.33
Munshi, N.C.34
Nakamura, H.35
Northcott, P.A.36
Pajic, M.37
Papaemmanuil, E.38
Paradiso, A.39
Pearson, J.V.40
Puente, X.S.41
Raine, K.42
Ramakrishna, M.43
Richardson, A.L.44
Richter, J.45
Rosenstiel, P.46
Schlesner, M.47
Schumacher, T.N.48
Span, P.N.49
Teague, J.W.50
Totoki, Y.51
Tutt, A.N.52
Valdes-Mas, R.53
van Buuren, M.M.54
van 't Veer, L.55
Vincent-Salomon, A.56
Waddell, N.57
Yates, L.R.58
Zucman-Rossi, J.59
Futreal, P.A.60
McDermott, U.61
Lichter, P.62
Meyerson, M.63
Grimmond, S.M.64
Siebert, R.65
Campo, E.66
Shibata, T.67
Pfister, S.M.68
Campbell, P.J.69
Stratton, M.R.70
more..
-
2
-
-
84952639653
-
Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
-
Andersen Rikke, Danio Marco, Borch Troels Holz, Steensgaard Eva Ellebæk, Iversen Trine Zeeberg, Kongsted Per, Andersen Mads Hald, thor Straten Per, Svane Inge Marie Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma. J. Immunother. Cancer 2014, 2:1.
-
(2014)
J. Immunother. Cancer
, vol.2
, pp. 1
-
-
Andersen, R.1
Danio, M.2
Borch, T.H.3
Steensgaard Eva, Ellebæk4
Iversen, T.Z.5
Kongsted, P.6
Andersen, M.H.7
thor Straten, P.8
Svane, I.M.9
-
3
-
-
20044363610
-
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
-
Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R., Palmer D.C., Chan C.C., KlebanoffC.A., Overwijk W.W., Rosenberg S.A., Restifo N.P. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174:2591-2601.
-
(2005)
J. Immunol.
, vol.174
, pp. 2591-2601
-
-
Antony, P.A.1
Piccirillo, C.A.2
Akpinarli, A.3
Finkelstein, S.E.4
Speiss, P.J.5
Surman, D.R.6
Palmer, D.C.7
Chan, C.C.8
Klebanoff, C.A.9
Overwijk, W.W.10
Rosenberg, S.A.11
Restifo, N.P.12
-
4
-
-
0025859335
-
Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer
-
Aoki Y., Takakuwa K., Kodama S., Tanaka K., Takahashi M., Tokunaga A., Takahashi T. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res. 1991, 51:1934-1939.
-
(1991)
Cancer Res.
, vol.51
, pp. 1934-1939
-
-
Aoki, Y.1
Takakuwa, K.2
Kodama, S.3
Tanaka, K.4
Takahashi, M.5
Tokunaga, A.6
Takahashi, T.7
-
5
-
-
0033024863
-
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
-
Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., Rosenberg S.A. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999, 17:2105-2116.
-
(1999)
J. Clin. Oncol.
, vol.17
, pp. 2105-2116
-
-
Atkins, M.B.1
Lotze, M.T.2
Dutcher, J.P.3
Fisher, R.I.4
Weiss, G.5
Margolin, K.6
Abrams, J.7
Sznol, M.8
Parkinson, D.9
Hawkins, M.10
Paradise, C.11
Kunkel, L.12
Rosenberg, S.A.13
-
6
-
-
0027958312
-
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
-
Bakker A.B., Schreurs M.W., de Boer A.J., Kawakami Y., Rosenberg S.A., Adema G.J., Figdor C.G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 1994, 179:1005-1009.
-
(1994)
J. Exp. Med.
, vol.179
, pp. 1005-1009
-
-
Bakker, A.B.1
Schreurs, M.W.2
de Boer, A.J.3
Kawakami, Y.4
Rosenberg, S.A.5
Adema, G.J.6
Figdor, C.G.7
-
7
-
-
84928763657
-
Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma
-
Baldan V., Griffiths R., Hawkins R.E., Gilham D.E. Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br. J. Cancer 2015, 112:1510-1518.
-
(2015)
Br. J. Cancer
, vol.112
, pp. 1510-1518
-
-
Baldan, V.1
Griffiths, R.2
Hawkins, R.E.3
Gilham, D.E.4
-
8
-
-
84892946785
-
Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
-
Balermpas P., Michel Y., Wagenblast J., Seitz O., Weiss C., Rodel F., Rodel C., Fokas E. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br. J. Cancer 2014, 110:501-509.
-
(2014)
Br. J. Cancer
, vol.110
, pp. 501-509
-
-
Balermpas, P.1
Michel, Y.2
Wagenblast, J.3
Seitz, O.4
Weiss, C.5
Rodel, F.6
Rodel, C.7
Fokas, E.8
-
9
-
-
0034781060
-
Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay
-
Becker C., Pohla H., Frankenberger B., Schuler T., Assenmacher M., Schendel D.J., Blankenstein T. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat. Med. 2001, 7:1159-1162.
-
(2001)
Nat. Med.
, vol.7
, pp. 1159-1162
-
-
Becker, C.1
Pohla, H.2
Frankenberger, B.3
Schuler, T.4
Assenmacher, M.5
Schendel, D.J.6
Blankenstein, T.7
-
10
-
-
0018906201
-
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor
-
Berendt M.J., North R.J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 1980, 151:69-80.
-
(1980)
J. Exp. Med.
, vol.151
, pp. 69-80
-
-
Berendt, M.J.1
North, R.J.2
-
11
-
-
0016531488
-
Syngeneic adoptive immunotherapy and chemoimmunotherapy of a friend leukemia: requirement for T cells
-
Berenson J.R., Einstein A.B., Fefer A. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a friend leukemia: requirement for T cells. J. Immunol. 1975, 115:234-238.
-
(1975)
J. Immunol.
, vol.115
, pp. 234-238
-
-
Berenson, J.R.1
Einstein, A.B.2
Fefer, A.3
-
12
-
-
84883472041
-
Adoptive transfer of tumor infiltrating lymphocytes in metastatic melanoma patients: intent-to-treat analysis and efficacy after failure to prior immunotherapies
-
Besser M.J., Shapira-Frommer R., Itzhaki O., Treves A.J., Zippel D., Levy D., Kubi A., Shoshani N., Zikich D., Ohayon Y., Ohayon D., Shalmon B., Markel G., Yerushalmi R., Apter S., Ben-Nun A., Ben-Ami E., Shimoni A., Nagler A., Schachter J. Adoptive transfer of tumor infiltrating lymphocytes in metastatic melanoma patients: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 2013, 19:4792-4800.
-
(2013)
Clin. Cancer Res.
, vol.19
, pp. 4792-4800
-
-
Besser, M.J.1
Shapira-Frommer, R.2
Itzhaki, O.3
Treves, A.J.4
Zippel, D.5
Levy, D.6
Kubi, A.7
Shoshani, N.8
Zikich, D.9
Ohayon, Y.10
Ohayon, D.11
Shalmon, B.12
Markel, G.13
Yerushalmi, R.14
Apter, S.15
Ben-Nun, A.16
Ben-Ami, E.17
Shimoni, A.18
Nagler, A.19
Schachter, J.20
more..
-
13
-
-
0018187313
-
In situ lymphoid cells of mouse mammary tumors. I. Development and evaluation of a method for the separation of lymphoid cells from mouse mammary tumors
-
Blazar B.A., Heppner G.H. In situ lymphoid cells of mouse mammary tumors. I. Development and evaluation of a method for the separation of lymphoid cells from mouse mammary tumors. J. Immunol. 1978, 120:1876-1880.
-
(1978)
J. Immunol.
, vol.120
, pp. 1876-1880
-
-
Blazar, B.A.1
Heppner, G.H.2
-
14
-
-
0028919215
-
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes
-
Castelli C., Storkus W.J., Maeurer M.J., Martin D.M., Huang E.C., Pramanik B.N., Nagabhushan T.L., Parmiani G., Lotze M.T. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J. Exp. Med. 1995, 181:363-368.
-
(1995)
J. Exp. Med.
, vol.181
, pp. 363-368
-
-
Castelli, C.1
Storkus, W.J.2
Maeurer, M.J.3
Martin, D.M.4
Huang, E.C.5
Pramanik, B.N.6
Nagabhushan, T.L.7
Parmiani, G.8
Lotze, M.T.9
-
15
-
-
84890277186
-
Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy
-
Chacon J.A., Pilon-Thomas S., Sarnaik A.A., Radvanyi L.G. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology 2013, 2:e25581.
-
(2013)
Oncoimmunology
, vol.2
-
-
Chacon, J.A.1
Pilon-Thomas, S.2
Sarnaik, A.A.3
Radvanyi, L.G.4
-
16
-
-
85021164263
-
Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
-
Chacon J.A., Sarnaik A.A., Chen J.Q., Creasy C., Kale C., Robinson J., Weber J., Hwu P., Pilon-Thomas S., Radvanyi L. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Clin. Cancer Res. 2015, 21:611-621.
-
(2015)
Clin. Cancer Res.
, vol.21
, pp. 611-621
-
-
Chacon, J.A.1
Sarnaik, A.A.2
Chen, J.Q.3
Creasy, C.4
Kale, C.5
Robinson, J.6
Weber, J.7
Hwu, P.8
Pilon-Thomas, S.9
Radvanyi, L.10
-
17
-
-
84936941924
-
A lineage-specific methylation pattern controls the transcription of the polycistronic mRNA coding MELOE melanoma antigens
-
Chalopin B., Florenceau L., Fradin D., Labarriere N., Moreau-Aubry A. A lineage-specific methylation pattern controls the transcription of the polycistronic mRNA coding MELOE melanoma antigens. Melanoma Res. 2015, 25:279-283.
-
(2015)
Melanoma Res.
, vol.25
, pp. 279-283
-
-
Chalopin, B.1
Florenceau, L.2
Fradin, D.3
Labarriere, N.4
Moreau-Aubry, A.5
-
18
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
Dummer, R.7
Garbe, C.8
Testori, A.9
Maio, M.10
Hogg, D.11
Lorigan, P.12
Lebbe, C.13
Jouary, T.14
Schadendorf, D.15
Ribas, A.16
O'Day, S.J.17
Sosman, J.A.18
Kirkwood, J.M.19
Eggermont, A.M.20
Dreno, B.21
Nolop, K.22
Li, J.23
Nelson, B.24
Hou, J.25
Lee, R.J.26
Flaherty, K.T.27
McArthur, G.A.28
more..
-
19
-
-
0018934336
-
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors
-
Cheever M.A., Greenberg P.D., Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 1980, 125:711-714.
-
(1980)
J. Immunol.
, vol.125
, pp. 711-714
-
-
Cheever, M.A.1
Greenberg, P.D.2
Fefer, A.3
-
20
-
-
0032499710
-
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library
-
Chen Y.T., Gure A.O., Tsang S., Stockert E., Jager E., Knuth A., Old L.J. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6919-6923.
-
(1998)
Proc. Natl. Acad. Sci. U. S. A.
, vol.95
, pp. 6919-6923
-
-
Chen, Y.T.1
Gure, A.O.2
Tsang, S.3
Stockert, E.4
Jager, E.5
Knuth, A.6
Old, L.J.7
-
21
-
-
0029925375
-
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
-
Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
-
(1996)
Cancer
, vol.77
, pp. 1303-1310
-
-
Clemente, C.G.1
Mihm, M.C.2
Bufalino, R.3
Zurrida, S.4
Collini, P.5
Cascinelli, N.6
-
22
-
-
0037174674
-
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
-
Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
-
(2002)
Science
, vol.298
, pp. 850-854
-
-
Dudley, M.E.1
Wunderlich, J.R.2
Robbins, P.F.3
Yang, J.C.4
Hwu, P.5
Schwartzentruber, D.J.6
Topalian, S.L.7
Sherry, R.8
Restifo, N.P.9
Hubicki, A.M.10
Robinson, M.R.11
Raffeld, M.12
Duray, P.13
Seipp, C.A.14
Rogers-Freezer, L.15
Morton, K.E.16
Mavroukakis, S.A.17
White, D.E.18
Rosenberg, S.A.19
-
23
-
-
0037829421
-
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
-
Dudley M.E., Wunderlich J.R., Shelton T.E., Even J., Rosenberg S.A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2003, 26:332-342.
-
(2003)
J. Immunother.
, vol.26
, pp. 332-342
-
-
Dudley, M.E.1
Wunderlich, J.R.2
Shelton, T.E.3
Even, J.4
Rosenberg, S.A.5
-
24
-
-
20244366111
-
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
-
Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., Jones S.A., Mangiameli D.P., Pelletier M.M., Gea-Banacloche J., Robinson M.R., Berman D.M., Filie A.C., Abati A., Rosenberg S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346-2357.
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 2346-2357
-
-
Dudley, M.E.1
Wunderlich, J.R.2
Yang, J.C.3
Sherry, R.M.4
Topalian, S.L.5
Restifo, N.P.6
Royal, R.E.7
Kammula, U.8
White, D.E.9
Mavroukakis, S.A.10
Rogers, L.J.11
Gracia, G.J.12
Jones, S.A.13
Mangiameli, D.P.14
Pelletier, M.M.15
Gea-Banacloche, J.16
Robinson, M.R.17
Berman, D.M.18
Filie, A.C.19
Abati, A.20
Rosenberg, S.A.21
more..
-
25
-
-
55949125601
-
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
-
Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 5233-5239
-
-
Dudley, M.E.1
Yang, J.C.2
Sherry, R.3
Hughes, M.S.4
Royal, R.5
Kammula, U.6
Robbins, P.F.7
Huang, J.8
Citrin, D.E.9
Leitman, S.F.10
Wunderlich, J.11
Restifo, N.P.12
Thomasian, A.13
Downey, S.G.14
Smith, F.O.15
Klapper, J.16
Morton, K.17
Laurencot, C.18
White, D.E.19
Rosenberg, S.A.20
more..
-
26
-
-
78650316191
-
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma
-
Dudley M.E., Gross C.A., Langhan M.M., Garcia M.R., Sherry R.M., Yang J.C., Phan G.Q., Kammula U.S., Hughes M.S., Citrin D.E., Restifo N.P., Wunderlich J.R., Prieto P.A., Hong J.J., Langan R.C., Zlott D.A., Morton K.E., White D.E., Laurencot C.M., Rosenberg S.A. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 2010, 16:6122-6131.
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 6122-6131
-
-
Dudley, M.E.1
Gross, C.A.2
Langhan, M.M.3
Garcia, M.R.4
Sherry, R.M.5
Yang, J.C.6
Phan, G.Q.7
Kammula, U.S.8
Hughes, M.S.9
Citrin, D.E.10
Restifo, N.P.11
Wunderlich, J.R.12
Prieto, P.A.13
Hong, J.J.14
Langan, R.C.15
Zlott, D.A.16
Morton, K.E.17
White, D.E.18
Laurencot, C.M.19
Rosenberg, S.A.20
more..
-
27
-
-
84887991307
-
Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma
-
Dudley M.E., Gross C.A., Somerville R.P., Hong Y., Schaub N.P., Rosati S.F., White D.E., Nathan D., Restifo N.P., Steinberg S.M., Wunderlich J.R., Kammula U.S., Sherry R.M., Yang J.C., Phan G.Q., Hughes M.S., Laurencot C.M., Rosenberg S.A. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 2013, 31:2152-2159.
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 2152-2159
-
-
Dudley, M.E.1
Gross, C.A.2
Somerville, R.P.3
Hong, Y.4
Schaub, N.P.5
Rosati, S.F.6
White, D.E.7
Nathan, D.8
Restifo, N.P.9
Steinberg, S.M.10
Wunderlich, J.R.11
Kammula, U.S.12
Sherry, R.M.13
Yang, J.C.14
Phan, G.Q.15
Hughes, M.S.16
Laurencot, C.M.17
Rosenberg, S.A.18
-
28
-
-
0019969717
-
Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2
-
Eberlein T.J., Rosenstein M., Rosenberg S.A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J. Exp. Med. 1982, 156:385-397.
-
(1982)
J. Exp. Med.
, vol.156
, pp. 385-397
-
-
Eberlein, T.J.1
Rosenstein, M.2
Rosenberg, S.A.3
-
29
-
-
84865079230
-
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
-
Ellebaek E., Iversen T.Z., Junker N., Donia M., Engell-Noerregaard L., Met O., Holmich L.R., Andersen R.S., Hadrup S.R., Andersen M.H., thor Straten P., Svane I.M. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J. Transl. Med. 2012, 10:169.
-
(2012)
J. Transl. Med.
, vol.10
, pp. 169
-
-
Ellebaek, E.1
Iversen, T.Z.2
Junker, N.3
Donia, M.4
Engell-Noerregaard, L.5
Met, O.6
Holmich, L.R.7
Andersen, R.S.8
Hadrup, S.R.9
Andersen, M.H.10
thor Straten, P.11
Svane, I.M.12
-
30
-
-
0036812718
-
Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy
-
Engelhard V.H., Bullock T.N., Colella T.A., Sheasley S.L., Mullins D.W. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 2002, 188:136-146.
-
(2002)
Immunol. Rev.
, vol.188
, pp. 136-146
-
-
Engelhard, V.H.1
Bullock, T.N.2
Colella, T.A.3
Sheasley, S.L.4
Mullins, D.W.5
-
31
-
-
0029682320
-
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes
-
Freedman R.S., Platsoucas C.D. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat. Res. 1996, 82:115-146.
-
(1996)
Cancer Treat. Res.
, vol.82
, pp. 115-146
-
-
Freedman, R.S.1
Platsoucas, C.D.2
-
32
-
-
84858800620
-
The immune contexture in human tumours: impact on clinical outcome
-
Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 298-306
-
-
Fridman, W.H.1
Pages, F.2
Sautes-Fridman, C.3
Galon, J.4
-
33
-
-
84861231609
-
Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes
-
Friedman K.M., Prieto P.A., Devillier L.E., Gross C.A., Yang J.C., Wunderlich J.R., Rosenberg S.A., Dudley M.E. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J. Immunother. 2012, 35:400-408.
-
(2012)
J. Immunother.
, vol.35
, pp. 400-408
-
-
Friedman, K.M.1
Prieto, P.A.2
Devillier, L.E.3
Gross, C.A.4
Yang, J.C.5
Wunderlich, J.R.6
Rosenberg, S.A.7
Dudley, M.E.8
-
34
-
-
0029049890
-
Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes
-
Fujita K., Ikarashi H., Takakuwa K., Kodama S., Tokunaga A., Takahashi T., Tanaka K. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin. Cancer Res. 1995, 1:501-507.
-
(1995)
Clin. Cancer Res.
, vol.1
, pp. 501-507
-
-
Fujita, K.1
Ikarashi, H.2
Takakuwa, K.3
Kodama, S.4
Tokunaga, A.5
Takahashi, T.6
Tanaka, K.7
-
35
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoue F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
-
(2006)
Science
, vol.313
, pp. 1960-1964
-
-
Galon, J.1
Costes, A.2
Sanchez-Cabo, F.3
Kirilovsky, A.4
Mlecnik, B.5
Lagorce-Pages, C.6
Tosolini, M.7
Camus, M.8
Berger, A.9
Wind, P.10
Zinzindohoue, F.11
Bruneval, P.12
Cugnenc, P.H.13
Trajanoski, Z.14
Fridman, W.H.15
Pages, F.16
-
36
-
-
25844484607
-
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
-
Gattinoni L., Finkelstein S.E., KlebanoffC.A., Antony P.A., Palmer D.C., Spiess P.J., Hwang L.N., Yu Z., Wrzesinski C., Heimann D.M., Surh C.D., Rosenberg S.A., Restifo N.P. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907-912.
-
(2005)
J. Exp. Med.
, vol.202
, pp. 907-912
-
-
Gattinoni, L.1
Finkelstein, S.E.2
Klebanoff, C.A.3
Antony, P.A.4
Palmer, D.C.5
Spiess, P.J.6
Hwang, L.N.7
Yu, Z.8
Wrzesinski, C.9
Heimann, D.M.10
Surh, C.D.11
Rosenberg, S.A.12
Restifo, N.P.13
-
37
-
-
58149153043
-
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency
-
Godet Y., Moreau-Aubry A., Guilloux Y., Vignard V., Khammari A., Dreno B., Jotereau F., Labarriere N. MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J. Exp. Med. 2008, 205:2673-2682.
-
(2008)
J. Exp. Med.
, vol.205
, pp. 2673-2682
-
-
Godet, Y.1
Moreau-Aubry, A.2
Guilloux, Y.3
Vignard, V.4
Khammari, A.5
Dreno, B.6
Jotereau, F.7
Labarriere, N.8
-
38
-
-
79959745851
-
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
-
Gooden M.J., de Bock G.H., Leffers N., Daemen T., Nijman H.W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 2011, 105:93-103.
-
(2011)
Br. J. Cancer
, vol.105
, pp. 93-103
-
-
Gooden, M.J.1
de Bock, G.H.2
Leffers, N.3
Daemen, T.4
Nijman, H.W.5
-
39
-
-
84899748384
-
PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors
-
Gros A., Robbins P.F., Yao X., Li Y.F., Turcotte S., Tran E., Wunderlich J.R., Mixon A., Farid S., Dudley M.E., Hanada K., Almeida J.R., Darko S., Douek D.C., Yang J.C., Rosenberg S.A. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 2014, 124:2246-2259.
-
(2014)
J. Clin. Invest.
, vol.124
, pp. 2246-2259
-
-
Gros, A.1
Robbins, P.F.2
Yao, X.3
Li, Y.F.4
Turcotte, S.5
Tran, E.6
Wunderlich, J.R.7
Mixon, A.8
Farid, S.9
Dudley, M.E.10
Hanada, K.11
Almeida, J.R.12
Darko, S.13
Douek, D.C.14
Yang, J.C.15
Rosenberg, S.A.16
-
40
-
-
67649616555
-
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers
-
Hadrup S.R., Bakker A.H., Shu C.J., Andersen R.S., van Veluw J., Hombrink P., Castermans E., Thor Straten P., Blank C., Haanen J.B., Heemskerk M.H., Schumacher T.N. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat. Methods 2009, 6:520-526.
-
(2009)
Nat. Methods
, vol.6
, pp. 520-526
-
-
Hadrup, S.R.1
Bakker, A.H.2
Shu, C.J.3
Andersen, R.S.4
van Veluw, J.5
Hombrink, P.6
Castermans, E.7
Thor Straten, P.8
Blank, C.9
Haanen, J.B.10
Heemskerk, M.H.11
Schumacher, T.N.12
-
41
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Kaempgen E., Martin-Algarra S., Karaszewska B., Mauch C., Chiarion-Sileni V., Martin A.M., Swann S., Haney P., Mirakhur B., Guckert M.E., Goodman V., Chapman P.B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
Jouary, T.4
Gutzmer, R.5
Millward, M.6
Rutkowski, P.7
Blank, C.U.8
Miller, W.H.9
Kaempgen, E.10
Martin-Algarra, S.11
Karaszewska, B.12
Mauch, C.13
Chiarion-Sileni, V.14
Martin, A.M.15
Swann, S.16
Haney, P.17
Mirakhur, B.18
Guckert, M.E.19
Goodman, V.20
Chapman, P.B.21
more..
-
42
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.9
Hassel, J.C.10
Akerley, W.11
van den Eertwegh, A.J.12
Lutzky, J.13
Lorigan, P.14
Vaubel, J.M.15
Linette, G.P.16
Hogg, D.17
Ottensmeier, C.H.18
Lebbe, C.19
Peschel, C.20
Quirt, I.21
Clark, J.I.22
Wolchok, J.D.23
Weber, J.S.24
Tian, J.25
Yellin, M.J.26
Nichol, G.M.27
Hoos, A.28
Urba, W.J.29
more..
-
43
-
-
17844381006
-
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression
-
Huang J., Khong H.T., Dudley M.E., El-Gamil M., Li Y.F., Rosenberg S.A., Robbins P.F. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 2005, 28:258-267.
-
(2005)
J. Immunother.
, vol.28
, pp. 258-267
-
-
Huang, J.1
Khong, H.T.2
Dudley, M.E.3
El-Gamil, M.4
Li, Y.F.5
Rosenberg, S.A.6
Robbins, P.F.7
-
44
-
-
33744940000
-
Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy
-
Huang J., Kerstann K.W., Ahmadzadeh M., Li Y.F., El-Gamil M., Rosenberg S.A., Robbins P.F. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J. Immunol. 2006, 176:7726-7735.
-
(2006)
J. Immunol.
, vol.176
, pp. 7726-7735
-
-
Huang, J.1
Kerstann, K.W.2
Ahmadzadeh, M.3
Li, Y.F.4
El-Gamil, M.5
Rosenberg, S.A.6
Robbins, P.F.7
-
45
-
-
84856021596
-
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis
-
Hwang W.T., Adams S.F., Tahirovic E., Hagemann I.S., Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 2012, 124:192-198.
-
(2012)
Gynecol. Oncol.
, vol.124
, pp. 192-198
-
-
Hwang, W.T.1
Adams, S.F.2
Tahirovic, E.3
Hagemann, I.S.4
Coukos, G.5
-
46
-
-
79953033883
-
Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy
-
Itzhaki O., Hovav E., Ziporen Y., Levy D., Kubi A., Zikich D., Hershkovitz L., Treves A.J., Shalmon B., Zippel D., Markel G., Shapira-Frommer R., Schachter J., Besser M.J. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J. Immunother. 2011, 34:212-220.
-
(2011)
J. Immunother.
, vol.34
, pp. 212-220
-
-
Itzhaki, O.1
Hovav, E.2
Ziporen, Y.3
Levy, D.4
Kubi, A.5
Zikich, D.6
Hershkovitz, L.7
Treves, A.J.8
Shalmon, B.9
Zippel, D.10
Markel, G.11
Shapira-Frommer, R.12
Schachter, J.13
Besser, M.J.14
-
47
-
-
84860389787
-
Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer
-
Junker N., Andersen M.H., Wenandy L., Dombernowsky S.L., Kiss K., Sorensen C.H., Therkildsen M.H., Von Buchwald C., Andersen E., Straten P.T., Svane I.M. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy 2011, 13:822-834.
-
(2011)
Cytotherapy
, vol.13
, pp. 822-834
-
-
Junker, N.1
Andersen, M.H.2
Wenandy, L.3
Dombernowsky, S.L.4
Kiss, K.5
Sorensen, C.H.6
Therkildsen, M.H.7
Von Buchwald, C.8
Andersen, E.9
Straten, P.T.10
Svane, I.M.11
-
48
-
-
0028298174
-
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
-
Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Sakaguchi K., Appella E., Yannelli J.R., Adema G.J., Miki T., Rosenberg S.A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U. S. A 1994, 91:6458-6462.
-
(1994)
Proc. Natl. Acad. Sci. U. S. A
, vol.91
, pp. 6458-6462
-
-
Kawakami, Y.1
Eliyahu, S.2
Delgado, C.H.3
Robbins, P.F.4
Sakaguchi, K.5
Appella, E.6
Yannelli, J.R.7
Adema, G.J.8
Miki, T.9
Rosenberg, S.A.10
-
49
-
-
0031406876
-
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
-
Keilholz U., Stoter G., Punt C.J., Scheibenbogen C., Lejeune F., Eggermont A.M. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J. Sci. Am. 1997, 3(Suppl. 1):S22-S28.
-
(1997)
Cancer J. Sci. Am.
, vol.3
, pp. S22-S28
-
-
Keilholz, U.1
Stoter, G.2
Punt, C.J.3
Scheibenbogen, C.4
Lejeune, F.5
Eggermont, A.M.6
-
50
-
-
84868255419
-
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?
-
KlebanoffC.A., Gattinoni L., Restifo N.P. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. J. Immunother. 2012, 35:651-660.
-
(2012)
J. Immunother.
, vol.35
, pp. 651-660
-
-
Klebanoff, C.A.1
Gattinoni, L.2
Restifo, N.P.3
-
51
-
-
84886944933
-
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients
-
Kvistborg P., Shu C.J., Heemskerk B., Fankhauser M., Thrue C.A., Toebes M., van Rooij N., Linnemann C., van Buuren M.M., Urbanus J.H., Beltman J.B., Thor Straten P., Li Y.F., Robbins P.F., Besser M.J., Schachter J., Kenter G.G., Dudley M.E., Rosenberg S.A., Haanen J.B., Hadrup S.R., Schumacher T.N. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012, 1:409-418.
-
(2012)
Oncoimmunology
, vol.1
, pp. 409-418
-
-
Kvistborg, P.1
Shu, C.J.2
Heemskerk, B.3
Fankhauser, M.4
Thrue, C.A.5
Toebes, M.6
van Rooij, N.7
Linnemann, C.8
van Buuren, M.M.9
Urbanus, J.H.10
Beltman, J.B.11
Thor Straten, P.12
Li, Y.F.13
Robbins, P.F.14
Besser, M.J.15
Schachter, J.16
Kenter, G.G.17
Dudley, M.E.18
Rosenberg, S.A.19
Haanen, J.B.20
Hadrup, S.R.21
Schumacher, T.N.22
more..
-
52
-
-
84925490541
-
Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients
-
Landskron J., Helland O., Torgersen K.M., Aandahl E.M., Gjertsen B.T., Bjorge L., Tasken K. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunol. Immunother. 2015, 64:337-347.
-
(2015)
Cancer Immunol. Immunother.
, vol.64
, pp. 337-347
-
-
Landskron, J.1
Helland, O.2
Torgersen, K.M.3
Aandahl, E.M.4
Gjertsen, B.T.5
Bjorge, L.6
Tasken, K.7
-
53
-
-
84908245075
-
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
-
Larkin J., Ascierto P.A., Dreno B., Atkinson V., Liszkay G., Maio M., Mandala M., Demidov L., Stroyakovskiy D., Thomas L., de la Cruz-Merino L., Dutriaux C., Garbe C., Sovak M.A., Chang I., Choong N., Hack S.P., McArthur G.A., Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014, 371:1867-1876.
-
(2014)
N. Engl. J. Med.
, vol.371
, pp. 1867-1876
-
-
Larkin, J.1
Ascierto, P.A.2
Dreno, B.3
Atkinson, V.4
Liszkay, G.5
Maio, M.6
Mandala, M.7
Demidov, L.8
Stroyakovskiy, D.9
Thomas, L.10
de la Cruz-Merino, L.11
Dutriaux, C.12
Garbe, C.13
Sovak, M.A.14
Chang, I.15
Choong, N.16
Hack, S.P.17
McArthur, G.A.18
Ribas, A.19
-
54
-
-
73949086540
-
MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro
-
Li Y., Liu S., Hernandez J., Vence L., Hwu P., Radvanyi L. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J. Immunol. 2010, 184:452-465.
-
(2010)
J. Immunol.
, vol.184
, pp. 452-465
-
-
Li, Y.1
Liu, S.2
Hernandez, J.3
Vence, L.4
Hwu, P.5
Radvanyi, L.6
-
55
-
-
84961323160
-
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma
-
Linnemann C., van Buuren M.M., Bies L., Verdegaal E.M., Schotte R., Calis J.J., Behjati S., Velds A., Hilkmann H., Atmioui D.E., Visser M., Stratton M.R., Haanen J.B., Spits H., van der Burg S.H., Schumacher T.N. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 2015, 21:81-85.
-
(2015)
Nat. Med.
, vol.21
, pp. 81-85
-
-
Linnemann, C.1
van Buuren, M.M.2
Bies, L.3
Verdegaal, E.M.4
Schotte, R.5
Calis, J.J.6
Behjati, S.7
Velds, A.8
Hilkmann, H.9
Atmioui, D.E.10
Visser, M.11
Stratton, M.R.12
Haanen, J.B.13
Spits, H.14
van der Burg, S.H.15
Schumacher, T.N.16
-
56
-
-
84908257665
-
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
-
Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J.J., Chiarion Sileni V., Lebbe C., Mandala M., Millward M., Arance A., Bondarenko I., Haanen J.B., Hansson J., Utikal J., Ferraresi V., Kovalenko N., Mohr P., Probachai V., Schadendorf D., Nathan P., Robert C., Ribas A., DeMarini D.J., Irani J.G., Casey M., Ouellet D., Martin A.M., Le N., Patel K., Flaherty K. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 2014, 371:1877-1888.
-
(2014)
N. Engl. J. Med.
, vol.371
, pp. 1877-1888
-
-
Long, G.V.1
Stroyakovskiy, D.2
Gogas, H.3
Levchenko, E.4
de Braud, F.5
Larkin, J.6
Garbe, C.7
Jouary, T.8
Hauschild, A.9
Grob, J.J.10
Chiarion Sileni, V.11
Lebbe, C.12
Mandala, M.13
Millward, M.14
Arance, A.15
Bondarenko, I.16
Haanen, J.B.17
Hansson, J.18
Utikal, J.19
Ferraresi, V.20
Kovalenko, N.21
Mohr, P.22
Probachai, V.23
Schadendorf, D.24
Nathan, P.25
Robert, C.26
Ribas, A.27
DeMarini, D.J.28
Irani, J.G.29
Casey, M.30
Ouellet, D.31
Martin, A.M.32
Le, N.33
Patel, K.34
Flaherty, K.35
more..
-
57
-
-
84903846565
-
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions
-
Lu Y.C., Yao X., Crystal J.S., Li Y.F., El-Gamil M., Gross C., Davis L., Dudley M.E., Yang J.C., Samuels Y., Rosenberg S.A., Robbins P.F. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 2014, 20:3401-3410.
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 3401-3410
-
-
Lu, Y.C.1
Yao, X.2
Crystal, J.S.3
Li, Y.F.4
El-Gamil, M.5
Gross, C.6
Davis, L.7
Dudley, M.E.8
Yang, J.C.9
Samuels, Y.10
Rosenberg, S.A.11
Robbins, P.F.12
-
58
-
-
84893856633
-
Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions
-
Maldonado L., Teague J.E., Morrow M.P., Jotova I., Wu T.C., Wang C., Desmarais C., Boyer J.D., Tycko B., Robins H.S., Clark R.A., Trimble C.L. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci. Transl. Med. 2014, 6:221ra213.
-
(2014)
Sci. Transl. Med.
, vol.6
-
-
Maldonado, L.1
Teague, J.E.2
Morrow, M.P.3
Jotova, I.4
Wu, T.C.5
Wang, C.6
Desmarais, C.7
Boyer, J.D.8
Tycko, B.9
Robins, H.S.10
Clark, R.A.11
Trimble, C.L.12
-
59
-
-
61449223099
-
Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma
-
Markel G., Cohen-Sinai T., Besser M.J., Oved K., Itzhaki O., Seidman R., Fridman E., Treves A.J., Keisari Y., Dotan Z., Ramon J., Schachter J. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Res. 2009, 29:145-154.
-
(2009)
Anticancer Res.
, vol.29
, pp. 145-154
-
-
Markel, G.1
Cohen-Sinai, T.2
Besser, M.J.3
Oved, K.4
Itzhaki, O.5
Seidman, R.6
Fridman, E.7
Treves, A.J.8
Keisari, Y.9
Dotan, Z.10
Ramon, J.11
Schachter, J.12
-
60
-
-
79952093380
-
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction
-
Mlecnik B., Tosolini M., Kirilovsky A., Berger A., Bindea G., Meatchi T., Bruneval P., Trajanoski Z., Fridman W.H., Pages F., Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 2011, 29:610-618.
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 610-618
-
-
Mlecnik, B.1
Tosolini, M.2
Kirilovsky, A.3
Berger, A.4
Bindea, G.5
Meatchi, T.6
Bruneval, P.7
Trajanoski, Z.8
Fridman, W.H.9
Pages, F.10
Galon, J.11
-
61
-
-
0023093741
-
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
-
Muul L.M., Spiess P.J., Director E.P., Rosenberg S.A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 1987, 138:989-995.
-
(1987)
J. Immunol.
, vol.138
, pp. 989-995
-
-
Muul, L.M.1
Spiess, P.J.2
Director, E.P.3
Rosenberg, S.A.4
-
62
-
-
0020047427
-
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
-
North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982, 155:1063-1074.
-
(1982)
J. Exp. Med.
, vol.155
, pp. 1063-1074
-
-
North, R.J.1
-
63
-
-
77649193013
-
Immune infiltration in human tumors: a prognostic factor that should not be ignored
-
Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C., Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093-1102.
-
(2010)
Oncogene
, vol.29
, pp. 1093-1102
-
-
Pages, F.1
Galon, J.2
Dieu-Nosjean, M.C.3
Tartour, E.4
Sautes-Fridman, C.5
Fridman, W.H.6
-
64
-
-
84866635452
-
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma
-
Pilon-Thomas S., Kuhn L., Ellwanger S., Janssen W., Royster E., Marzban S., Kudchadkar R., Zager J., Gibney G., Sondak V.K., Weber J., Mule J.J., Sarnaik A.A. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J. Immunother. 2012, 35:615-620.
-
(2012)
J. Immunother.
, vol.35
, pp. 615-620
-
-
Pilon-Thomas, S.1
Kuhn, L.2
Ellwanger, S.3
Janssen, W.4
Royster, E.5
Marzban, S.6
Kudchadkar, R.7
Zager, J.8
Gibney, G.9
Sondak, V.K.10
Weber, J.11
Mule, J.J.12
Sarnaik, A.A.13
-
65
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., Shaheen M., ErnstoffM.S., Minor D., Salama A.K., Taylor M., Ott P.A., Rollin L.M., Horak C., Gagnier P., Wolchok J.D., Hodi F.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 21:2006-2017.
-
(2015)
N. Engl. J. Med.
, vol.21
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
Robert, C.4
Grossmann, K.5
McDermott, D.6
Linette, G.P.7
Meyer, N.8
Giguere, J.K.9
Agarwala, S.S.10
Shaheen, M.11
Ernstoff, M.S.12
Minor, D.13
Salama, A.K.14
Taylor, M.15
Ott, P.A.16
Rollin, L.M.17
Horak, C.18
Gagnier, P.19
Wolchok, J.D.20
Hodi, F.S.21
more..
-
66
-
-
11144241310
-
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy
-
Powell D.J., Dudley M.E., Robbins P.F., Rosenberg S.A. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005, 105:241-250.
-
(2005)
Blood
, vol.105
, pp. 241-250
-
-
Powell, D.J.1
Dudley, M.E.2
Robbins, P.F.3
Rosenberg, S.A.4
-
67
-
-
77953044135
-
Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy
-
Prieto P.A., Durflinger K.H., Wunderlich J.R., Rosenberg S.A., Dudley M.E. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J. Immunother. 2010, 33:547-556.
-
(2010)
J. Immunother.
, vol.33
, pp. 547-556
-
-
Prieto, P.A.1
Durflinger, K.H.2
Wunderlich, J.R.3
Rosenberg, S.A.4
Dudley, M.E.5
-
68
-
-
84871207055
-
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients
-
Radvanyi L.G., Bernatchez C., Zhang M., Fox P.S., Miller P., Chacon J., Wu R., Lizee G., Mahoney S., Alvarado G., Glass M., Johnson V.E., McMannis J.D., Shpall E., Prieto V., Papadopoulos N., Kim K., Homsi J., Bedikian A., Hwu W.J., Patel S., Ross M.I., Lee J.E., Gershenwald J.E., Lucci A., Royal R., Cormier J.N., Davies M.A., Mansaray R., Fulbright O.J., Toth C., Ramachandran R., Wardell S., Gonzalez A., Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2012, 18:6758-6770.
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 6758-6770
-
-
Radvanyi, L.G.1
Bernatchez, C.2
Zhang, M.3
Fox, P.S.4
Miller, P.5
Chacon, J.6
Wu, R.7
Lizee, G.8
Mahoney, S.9
Alvarado, G.10
Glass, M.11
Johnson, V.E.12
McMannis, J.D.13
Shpall, E.14
Prieto, V.15
Papadopoulos, N.16
Kim, K.17
Homsi, J.18
Bedikian, A.19
Hwu, W.J.20
Patel, S.21
Ross, M.I.22
Lee, J.E.23
Gershenwald, J.E.24
Lucci, A.25
Royal, R.26
Cormier, J.N.27
Davies, M.A.28
Mansaray, R.29
Fulbright, O.J.30
Toth, C.31
Ramachandran, R.32
Wardell, S.33
Gonzalez, A.34
Hwu, P.35
more..
-
69
-
-
0028363683
-
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy
-
Robbins P.F., el-Gamil M., Kawakami Y., Stevens E., Yannelli J.R., Rosenberg S.A. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 1994, 54:3124-3126.
-
(1994)
Cancer Res.
, vol.54
, pp. 3124-3126
-
-
Robbins, P.F.1
el-Gamil, M.2
Kawakami, Y.3
Stevens, E.4
Yannelli, J.R.5
Rosenberg, S.A.6
-
70
-
-
0029669950
-
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
-
Robbins P.F., El-Gamil M., Li Y.F., Kawakami Y., Loftus D., Appella E., Rosenberg S.A. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 1996, 183:1185-1192.
-
(1996)
J. Exp. Med.
, vol.183
, pp. 1185-1192
-
-
Robbins, P.F.1
El-Gamil, M.2
Li, Y.F.3
Kawakami, Y.4
Loftus, D.5
Appella, E.6
Rosenberg, S.A.7
-
71
-
-
0037111530
-
Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
-
Robbins P.F., El-Gamil M., Li Y.F., Zeng G., Dudley M., Rosenberg S.A. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J. Immunol. 2002, 169:6036-6047.
-
(2002)
J. Immunol.
, vol.169
, pp. 6036-6047
-
-
Robbins, P.F.1
El-Gamil, M.2
Li, Y.F.3
Zeng, G.4
Dudley, M.5
Rosenberg, S.A.6
-
72
-
-
79952304769
-
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
-
Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., Kammula U.S., Hughes M.S., Restifo N.P., Raffeld M., Lee C.C., Levy C.L., Li Y.F., El-Gamil M., Schwarz S.L., Laurencot C., Rosenberg S.A. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29:917-924.
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 917-924
-
-
Robbins, P.F.1
Morgan, R.A.2
Feldman, S.A.3
Yang, J.C.4
Sherry, R.M.5
Dudley, M.E.6
Wunderlich, J.R.7
Nahvi, A.V.8
Helman, L.J.9
Mackall, C.L.10
Kammula, U.S.11
Hughes, M.S.12
Restifo, N.P.13
Raffeld, M.14
Lee, C.C.15
Levy, C.L.16
Li, Y.F.17
El-Gamil, M.18
Schwarz, S.L.19
Laurencot, C.20
Rosenberg, S.A.21
more..
-
73
-
-
84920394727
-
Improved overall survival in melanoma with combined dabrafenib and trametinib
-
Robert C., Karaszewska B., Schachter J., Rutkowski P., Mackiewicz A., Stroiakovski D., Lichinitser M., Dummer R., Grange F., Mortier L., Chiarion-Sileni V., Drucis K., Krajsova I., Hauschild A., Lorigan P., Wolter P., Long G.V., Flaherty K., Nathan P., Ribas A., Martin A.M., Sun P., Crist W., Legos J., Rubin S.D., Little S.M., Schadendorf D. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 2014, 372:30-39.
-
(2014)
N. Engl. J. Med.
, vol.372
, pp. 30-39
-
-
Robert, C.1
Karaszewska, B.2
Schachter, J.3
Rutkowski, P.4
Mackiewicz, A.5
Stroiakovski, D.6
Lichinitser, M.7
Dummer, R.8
Grange, F.9
Mortier, L.10
Chiarion-Sileni, V.11
Drucis, K.12
Krajsova, I.13
Hauschild, A.14
Lorigan, P.15
Wolter, P.16
Long, G.V.17
Flaherty, K.18
Nathan, P.19
Ribas, A.20
Martin, A.M.21
Sun, P.22
Crist, W.23
Legos, J.24
Rubin, S.D.25
Little, S.M.26
Schadendorf, D.27
more..
-
74
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., Savage K.J., Hernberg M.M., Lebbe C., Charles J., Mihalcioiu C., Chiarion-Sileni V., Mauch C., Cognetti F., Arance A., Schmidt H., Schadendorf D., Gogas H., Lundgren-Eriksson L., Horak C., Sharkey B., Waxman I.M., Atkinson V., Ascierto P.A. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372:320-330.
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
Dutriaux, C.4
Maio, M.5
Mortier, L.6
Hassel, J.C.7
Rutkowski, P.8
McNeil, C.9
Kalinka-Warzocha, E.10
Savage, K.J.11
Hernberg, M.M.12
Lebbe, C.13
Charles, J.14
Mihalcioiu, C.15
Chiarion-Sileni, V.16
Mauch, C.17
Cognetti, F.18
Arance, A.19
Schmidt, H.20
Schadendorf, D.21
Gogas, H.22
Lundgren-Eriksson, L.23
Horak, C.24
Sharkey, B.25
Waxman, I.M.26
Atkinson, V.27
Ascierto, P.A.28
more..
-
75
-
-
84929481481
-
Pembrolizumab versus ipilimumab in advanced melanoma
-
Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., Larkin J., Lorigan P., Neyns B., Blank C.U., Hamid O., Mateus C., Shapira-Frommer R., Kosh M., Zhou H., Ibrahim N., Ebbinghaus S., Ribas A., investigators K.- Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015, 372:2521-2532.
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 2521-2532
-
-
Robert, C.1
Schachter, J.2
Long, G.V.3
Arance, A.4
Grob, J.J.5
Mortier, L.6
Daud, A.7
Carlino, M.S.8
McNeil, C.9
Lotem, M.10
Larkin, J.11
Lorigan, P.12
Neyns, B.13
Blank, C.U.14
Hamid, O.15
Mateus, C.16
Shapira-Frommer, R.17
Kosh, M.18
Zhou, H.19
Ibrahim, N.20
Ebbinghaus, S.21
Ribas, A.22
more..
-
76
-
-
0031225690
-
Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
-
Romero P., Gervois N., Schneider J., Escobar P., Valmori D., Pannetier C., Steinle A., Wolfel T., Lienard D., Brichard V., van Pel A., Jotereau F., Cerottini J.C. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 1997, 159:2366-2374.
-
(1997)
J. Immunol.
, vol.159
, pp. 2366-2374
-
-
Romero, P.1
Gervois, N.2
Schneider, J.3
Escobar, P.4
Valmori, D.5
Pannetier, C.6
Steinle, A.7
Wolfel, T.8
Lienard, D.9
Brichard, V.10
van Pel, A.11
Jotereau, F.12
Cerottini, J.C.13
-
77
-
-
0022349817
-
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
-
Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., Matory Y.L., Skibber J.M., Shiloni E., Vetto J.T., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985, 313:1485-1492.
-
(1985)
N. Engl. J. Med.
, vol.313
, pp. 1485-1492
-
-
Rosenberg, S.A.1
Lotze, M.T.2
Muul, L.M.3
Leitman, S.4
Chang, A.E.5
Ettinghausen, S.E.6
Matory, Y.L.7
Skibber, J.M.8
Shiloni, E.9
Vetto, J.T.10
-
78
-
-
0022473607
-
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
-
Rosenberg S.A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321.
-
(1986)
Science
, vol.233
, pp. 1318-1321
-
-
Rosenberg, S.A.1
Spiess, P.2
Lafreniere, R.3
-
79
-
-
0028031582
-
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
-
Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994, 86:1159-1166.
-
(1994)
J. Natl. Cancer Inst.
, vol.86
, pp. 1159-1166
-
-
Rosenberg, S.A.1
Yannelli, J.R.2
Yang, J.C.3
Topalian, S.L.4
Schwartzentruber, D.J.5
Weber, J.S.6
Parkinson, D.R.7
Seipp, C.A.8
Einhorn, J.H.9
White, D.E.10
-
80
-
-
0032471712
-
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response
-
Rosenberg S.A., Yang J.C., White D.E., Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 1998, 228:307-319.
-
(1998)
Ann. Surg.
, vol.228
, pp. 307-319
-
-
Rosenberg, S.A.1
Yang, J.C.2
White, D.E.3
Steinberg, S.M.4
-
81
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
-
Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., Morton K.E., Laurencot C.M., Steinberg S.M., White D.E., Dudley M.E. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
Kammula, U.S.4
Hughes, M.S.5
Phan, G.Q.6
Citrin, D.E.7
Restifo, N.P.8
Robbins, P.F.9
Wunderlich, J.R.10
Morton, K.E.11
Laurencot, C.M.12
Steinberg, S.M.13
White, D.E.14
Dudley, M.E.15
-
83
-
-
0036813331
-
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
-
Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunolog. Rev. 2002, 188:22-32.
-
(2002)
Immunolog. Rev.
, vol.188
, pp. 22-32
-
-
Scanlan, M.J.1
Gure, A.O.2
Jungbluth, A.A.3
Old, L.J.4
Chen, Y.T.5
-
84
-
-
84928917822
-
Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
-
Schadendorf D., Hodi F.S., Robert C., Weber J.S., Margolin K., Hamid O., Patt D., Chen T.T., Berman D.M., Wolchok J.D. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 2015, 33:1889-1894.
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 1889-1894
-
-
Schadendorf, D.1
Hodi, F.S.2
Robert, C.3
Weber, J.S.4
Margolin, K.5
Hamid, O.6
Patt, D.7
Chen, T.T.8
Berman, D.M.9
Wolchok, J.D.10
-
85
-
-
0030851392
-
Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy
-
Schendel D.J., Oberneder R., Falk C.S., Jantzer P., Kressenstein S., Maget B., Hofstetter A., Riethmuller G., Nossner E. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J. Mol. Med. 1997, 75:400-413.
-
(1997)
J. Mol. Med.
, vol.75
, pp. 400-413
-
-
Schendel, D.J.1
Oberneder, R.2
Falk, C.S.3
Jantzer, P.4
Kressenstein, S.5
Maget, B.6
Hofstetter, A.7
Riethmuller, G.8
Nossner, E.9
-
86
-
-
84928770388
-
Neoantigens in cancer immunotherapy
-
Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
-
(2015)
Science
, vol.348
, pp. 69-74
-
-
Schumacher, T.N.1
Schreiber, R.D.2
-
87
-
-
0036836168
-
Managing toxicities of high-dose interleukin-2
-
Schwartz R.N., Stover L., Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology 2002, 16:11-20.
-
(2002)
Oncology
, vol.16
, pp. 11-20
-
-
Schwartz, R.N.1
Stover, L.2
Dutcher, J.3
-
88
-
-
0028304484
-
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
-
Schwartzentruber D.J., Hom S.S., Dadmarz R., White D.E., Yannelli J.R., Steinberg S.M., Rosenberg S.A., Topalian S.L. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 1994, 12:1475-1483.
-
(1994)
J. Clin. Oncol.
, vol.12
, pp. 1475-1483
-
-
Schwartzentruber, D.J.1
Hom, S.S.2
Dadmarz, R.3
White, D.E.4
Yannelli, J.R.5
Steinberg, S.M.6
Rosenberg, S.A.7
Topalian, S.L.8
-
89
-
-
70350716447
-
T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective
-
Shablak A., Hawkins R.E., Rothwell D.G., Elkord E. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin. Cancer Res. 2009, 15:6503-6510.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 6503-6510
-
-
Shablak, A.1
Hawkins, R.E.2
Rothwell, D.G.3
Elkord, E.4
-
90
-
-
0023640856
-
In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
-
Spiess P.J., Yang J.C., Rosenberg S.A. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst. 1987, 79:1067-1075.
-
(1987)
J. Natl. Cancer Inst.
, vol.79
, pp. 1067-1075
-
-
Spiess, P.J.1
Yang, J.C.2
Rosenberg, S.A.3
-
91
-
-
84933508708
-
Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells
-
Stevanovic S., Draper L.M., Langhan M.M., Campbell T.E., Kwong M.L., Wunderlich J.R., Dudley M.E., Yang J.C., Sherry R.M., Kammula U.S., Restifo N.P., Rosenberg S.A., Hinrichs C.S. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 2015, 33:1543-1550.
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 1543-1550
-
-
Stevanovic, S.1
Draper, L.M.2
Langhan, M.M.3
Campbell, T.E.4
Kwong, M.L.5
Wunderlich, J.R.6
Dudley, M.E.7
Yang, J.C.8
Sherry, R.M.9
Kammula, U.S.10
Restifo, N.P.11
Rosenberg, S.A.12
Hinrichs, C.S.13
-
92
-
-
32244442535
-
Design and use of conditional MHC class I ligands
-
Toebes M., Coccoris M., Bins A., Rodenko B., Gomez R., Nieuwkoop N.J., van de Kasteele W., Rimmelzwaan G.F., Haanen J.B., Ovaa H., Schumacher T.N. Design and use of conditional MHC class I ligands. Nat. Med. 2006, 12:246-251.
-
(2006)
Nat. Med.
, vol.12
, pp. 246-251
-
-
Toebes, M.1
Coccoris, M.2
Bins, A.3
Rodenko, B.4
Gomez, R.5
Nieuwkoop, N.J.6
van de Kasteele, W.7
Rimmelzwaan, G.F.8
Haanen, J.B.9
Ovaa, H.10
Schumacher, T.N.11
-
93
-
-
0023252348
-
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials
-
Topalian S.L., Muul L.M., Solomon D., Rosenberg S.A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 1987, 102:127-141.
-
(1987)
J. Immunol. Methods
, vol.102
, pp. 127-141
-
-
Topalian, S.L.1
Muul, L.M.2
Solomon, D.3
Rosenberg, S.A.4
-
94
-
-
0023934650
-
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study
-
Topalian S.L., Solomon D., Avis F.P., Chang A.E., Freerksen D.L., Linehan W.M., Lotze M.T., Robertson C.N., Seipp C.A., Simon P., et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 1988, 6:839-853.
-
(1988)
J. Clin. Oncol.
, vol.6
, pp. 839-853
-
-
Topalian, S.L.1
Solomon, D.2
Avis, F.P.3
Chang, A.E.4
Freerksen, D.L.5
Linehan, W.M.6
Lotze, M.T.7
Robertson, C.N.8
Seipp, C.A.9
Simon, P.10
-
95
-
-
59849100381
-
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
-
Tran K.Q., Zhou J., Durflinger K.H., Langhan M.M., Shelton T.E., Wunderlich J.R., Robbins P.F., Rosenberg S.A., Dudley M.E. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 2008, 31:742-751.
-
(2008)
J. Immunother.
, vol.31
, pp. 742-751
-
-
Tran, K.Q.1
Zhou, J.2
Durflinger, K.H.3
Langhan, M.M.4
Shelton, T.E.5
Wunderlich, J.R.6
Robbins, P.F.7
Rosenberg, S.A.8
Dudley, M.E.9
-
96
-
-
84900301377
-
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
-
Tran E., Turcotte S., Gros A., Robbins P.F., Lu Y.C., Dudley M.E., Wunderlich J.R., Somerville R.P., Hogan K., Hinrichs C.S., Parkhurst M.R., Yang J.C., Rosenberg S.A. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344:641-645.
-
(2014)
Science
, vol.344
, pp. 641-645
-
-
Tran, E.1
Turcotte, S.2
Gros, A.3
Robbins, P.F.4
Lu, Y.C.5
Dudley, M.E.6
Wunderlich, J.R.7
Somerville, R.P.8
Hogan, K.9
Hinrichs, C.S.10
Parkhurst, M.R.11
Yang, J.C.12
Rosenberg, S.A.13
-
97
-
-
0026645959
-
A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
-
Traversari C., van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 1992, 176:1453-1457.
-
(1992)
J. Exp. Med.
, vol.176
, pp. 1453-1457
-
-
Traversari, C.1
van der Bruggen, P.2
Luescher, I.F.3
Lurquin, C.4
Chomez, P.5
Van Pel, A.6
De Plaen, E.7
Amar-Costesec, A.8
Boon, T.9
-
98
-
-
84883433341
-
Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy
-
Turcotte S., Gros A., Hogan K., Tran E., Hinrichs C.S., Wunderlich J.R., Dudley M.E., Rosenberg S.A. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J. Immunol. 2013, 191:2217-2225.
-
(2013)
J. Immunol.
, vol.191
, pp. 2217-2225
-
-
Turcotte, S.1
Gros, A.2
Hogan, K.3
Tran, E.4
Hinrichs, C.S.5
Wunderlich, J.R.6
Dudley, M.E.7
Rosenberg, S.A.8
-
99
-
-
84892711807
-
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy
-
Turcotte S., Gros A., Tran E., Lee C.C., Wunderlich J.R., Robbins P.F., Rosenberg S.A. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin. Cancer Res. 2014, 20:331-343.
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 331-343
-
-
Turcotte, S.1
Gros, A.2
Tran, E.3
Lee, C.C.4
Wunderlich, J.R.5
Robbins, P.F.6
Rosenberg, S.A.7
-
100
-
-
0036780666
-
Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model
-
Tuthill R.J., Unger J.M., Liu P.Y., Flaherty L.E., Sondak V.K., Southwest Oncology G. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am. J. Clin. Pathol. 2002, 118:504-511.
-
(2002)
Am. J. Clin. Pathol.
, vol.118
, pp. 504-511
-
-
Tuthill, R.J.1
Unger, J.M.2
Liu, P.Y.3
Flaherty, L.E.4
Sondak, V.K.5
Southwest Oncology, G.6
-
101
-
-
84862496700
-
Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy
-
Ullenhag G.J., Sadeghi A.M., Carlsson B., Ahlstrom H., Mosavi F., Wagenius G., Totterman T.H. Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. Cancer Immunol. Immunother. 2012, 61:725-732.
-
(2012)
Cancer Immunol. Immunother.
, vol.61
, pp. 725-732
-
-
Ullenhag, G.J.1
Sadeghi, A.M.2
Carlsson, B.3
Ahlstrom, H.4
Mosavi, F.5
Wagenius, G.6
Totterman, T.H.7
-
102
-
-
84872841412
-
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
-
van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., van Dijk L.J., Behjati S., Hilkmann H., El Atmioui D., Nieuwland M., Stratton M.R., Kerkhoven R.M., Kesmir C., Haanen J.B., Kvistborg P., Schumacher T.N. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 2013, 31:e439-442.
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. e439-442
-
-
van Rooij, N.1
van Buuren, M.M.2
Philips, D.3
Velds, A.4
Toebes, M.5
Heemskerk, B.6
van Dijk, L.J.7
Behjati, S.8
Hilkmann, H.9
El Atmioui, D.10
Nieuwland, M.11
Stratton, M.R.12
Kerkhoven, R.M.13
Kesmir, C.14
Haanen, J.B.15
Kvistborg, P.16
Schumacher, T.N.17
-
104
-
-
0032840918
-
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
-
Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
-
(1999)
J. Pathol.
, vol.189
, pp. 12-19
-
-
Walboomers, J.M.1
Jacobs, M.V.2
Manos, M.M.3
Bosch, F.X.4
Kummer, J.A.5
Shah, K.V.6
Snijders, P.J.7
Peto, J.8
Meijer, C.J.9
Munoz, N.10
-
105
-
-
84870352830
-
Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma
-
Wang Q.J., Hanada K., Robbins P.F., Li Y.F., Yang J.C. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res. 2012, 72:6119-6129.
-
(2012)
Cancer Res.
, vol.72
, pp. 6119-6129
-
-
Wang, Q.J.1
Hanada, K.2
Robbins, P.F.3
Li, Y.F.4
Yang, J.C.5
-
106
-
-
84961288360
-
Immunoprevention of human papillomavirus-associated malignancies
-
Wang J.W., Hung C.F., Huh W.K., Trimble C.L., Roden R.B. Immunoprevention of human papillomavirus-associated malignancies. Cancer Prevent. Res. 2015, 8:95-104.
-
(2015)
Cancer Prevent. Res.
, vol.8
, pp. 95-104
-
-
Wang, J.W.1
Hung, C.F.2
Huh, W.K.3
Trimble, C.L.4
Roden, R.B.5
-
107
-
-
84892948376
-
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer
-
Ward M.J., Thirdborough S.M., Mellows T., Riley C., Harris S., Suchak K., Webb A., Hampton C., Patel N.N., Randall C.J., Cox H.J., Jogai S., Primrose J., Piper K., Ottensmeier C.H., King E.V., Thomas G.J. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br. J. Cancer 2014, 110:489-500.
-
(2014)
Br. J. Cancer
, vol.110
, pp. 489-500
-
-
Ward, M.J.1
Thirdborough, S.M.2
Mellows, T.3
Riley, C.4
Harris, S.5
Suchak, K.6
Webb, A.7
Hampton, C.8
Patel, N.N.9
Randall, C.J.10
Cox, H.J.11
Jogai, S.12
Primrose, J.13
Piper, K.14
Ottensmeier, C.H.15
King, E.V.16
Thomas, G.J.17
-
108
-
-
84962020040
-
PD-1 and CD103 are widely co-expressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer
-
Webb J.R., Milne K., Nelson B.H. PD-1 and CD103 are widely co-expressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer. Cancer Immunol. Res. 2015, 3:926-935.
-
(2015)
Cancer Immunol. Res.
, vol.3
, pp. 926-935
-
-
Webb, J.R.1
Milne, K.2
Nelson, B.H.3
-
109
-
-
84931083080
-
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
-
Weber J.S., D'Angelo S.P., Minor D., Hodi F.S., Gutzmer R., Neyns B., Hoeller C., Khushalani N.I., Miller W.H., Lao C.D., Linette G.P., Thomas L., Lorigan P., Grossmann K.F., Hassel J.C., Maio M., Sznol M., Ascierto P.A., Mohr P., Chmielowski B., Bryce A., Svane I.M., Grob J.J., Krackhardt A.M., Horak C., Lambert A., Yang A.S., Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015, 16:375-384.
-
(2015)
Lancet Oncol.
, vol.16
, pp. 375-384
-
-
Weber, J.S.1
D'Angelo, S.P.2
Minor, D.3
Hodi, F.S.4
Gutzmer, R.5
Neyns, B.6
Hoeller, C.7
Khushalani, N.I.8
Miller, W.H.9
Lao, C.D.10
Linette, G.P.11
Thomas, L.12
Lorigan, P.13
Grossmann, K.F.14
Hassel, J.C.15
Maio, M.16
Sznol, M.17
Ascierto, P.A.18
Mohr, P.19
Chmielowski, B.20
Bryce, A.21
Svane, I.M.22
Grob, J.J.23
Krackhardt, A.M.24
Horak, C.25
Lambert, A.26
Yang, A.S.27
Larkin, J.28
more..
-
110
-
-
84895835410
-
Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer
-
Wick D.A., Webb J.R., Nielsen J.S., Martin S.D., Kroeger D.R., Milne K., Castellarin M., Twumasi-Boateng K., Watson P.H., Holt R.A., Nelson B.H. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin. Cancer Res. 2014, 20:1125-1134.
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 1125-1134
-
-
Wick, D.A.1
Webb, J.R.2
Nielsen, J.S.3
Martin, S.D.4
Kroeger, D.R.5
Milne, K.6
Castellarin, M.7
Twumasi-Boateng, K.8
Watson, P.H.9
Holt, R.A.10
Nelson, B.H.11
-
111
-
-
0028978274
-
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
-
Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer zum Buschenfelde K.H., Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284.
-
(1995)
Science
, vol.269
, pp. 1281-1284
-
-
Wolfel, T.1
Hauer, M.2
Schneider, J.3
Serrano, M.4
Wolfel, C.5
Klehmann-Hieb, E.6
De Plaen, E.7
Hankeln, T.8
Meyer zum Buschenfelde, K.H.9
Beach, D.10
-
112
-
-
84862490985
-
Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
-
Yao X., Ahmadzadeh M., Lu Y.C., Liewehr D.J., Dudley M.E., Liu F., Schrump D.S., Steinberg S.M., Rosenberg S.A., Robbins P.F. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012, 119:5688-5696.
-
(2012)
Blood
, vol.119
, pp. 5688-5696
-
-
Yao, X.1
Ahmadzadeh, M.2
Lu, Y.C.3
Liewehr, D.J.4
Dudley, M.E.5
Liu, F.6
Schrump, D.S.7
Steinberg, S.M.8
Rosenberg, S.A.9
Robbins, P.F.10
-
113
-
-
84892164928
-
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor
-
Ye Q., Song D.G., Poussin M., Yamamoto T., Best A., Li C., Coukos G., Powell D.J. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 2014, 20:44-55.
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 44-55
-
-
Ye, Q.1
Song, D.G.2
Poussin, M.3
Yamamoto, T.4
Best, A.5
Li, C.6
Coukos, G.7
Powell, D.J.8
-
114
-
-
0015877691
-
Separation of lymphocytes from disaggregated mouse malignant neoplasms by sedimentation in gradients of ficoll in tissue culture medium
-
Zettergren J.G., LuberoffD.E., Pretlow T.G. Separation of lymphocytes from disaggregated mouse malignant neoplasms by sedimentation in gradients of ficoll in tissue culture medium. J. Immunol. 1973, 111:836-840.
-
(1973)
J. Immunol.
, vol.111
, pp. 836-840
-
-
Zettergren, J.G.1
Luberoff, D.E.2
Pretlow, T.G.3
-
115
-
-
0037448353
-
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
-
Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 203-213
-
-
Zhang, L.1
Conejo-Garcia, J.R.2
Katsaros, D.3
Gimotty, P.A.4
Massobrio, M.5
Regnani, G.6
Makrigiannakis, A.7
Gray, H.8
Schlienger, K.9
Liebman, M.N.10
Rubin, S.C.11
Coukos, G.12
-
116
-
-
84933564607
-
Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer
-
Zsiros E., Tsuji T., Odunsi K. Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer. J. Clin. Oncol. 2015, 33:1521-1522.
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 1521-1522
-
-
Zsiros, E.1
Tsuji, T.2
Odunsi, K.3
|